Lumaris gives pharmaceutical market access, HEOR, and medical affairs teams access to High Fidelity Patient Evidence, structured, prospective, patient sourced data collected during the 90 day post discharge window where adherence failure happens, readmission risk peaks, and every existing real world data platform loses the signal.
| Evidence Characteristic | Claims / EHR | Trisana HFPE |
|---|---|---|
| Data source | Administrative billing | Direct patient engagement |
| Adherence timing | Days or weeks after | Within 72 hours |
| SDOH data | Inferred from census | Direct patient reported |
| Behavioral signals | Not available | Self efficacy, barriers |
| Day 90 coverage | ~12% retention | Structured through Day 90 |
| Intervention layer | Observation only | Embedded case management |
TriunityCX defines High Fidelity Patient Evidence as prospective, patient sourced behavioral and social data collected through direct structured engagement at defined protocol intervals across the 90 day post discharge window. HFPE is not derived from administrative transactions or inferred from population level proxies. It is collected directly from the patient through a structured case management protocol that captures what the patient is actually doing, not what was billed on their behalf.
Existing platforms capture what was billed and what was dispensed, typically days or weeks after the clinical event occurred. Trisana captures what the patient is actually doing, within 72 hours of discharge, through direct structured engagement. That difference in data source produces a materially different category of evidence that is more behaviorally specific, more temporally precise, and more actionable for pharmaceutical market access and payer strategy than anything retrospective claims aggregation can produce.
Lumaris surfaces a suite of novel key performance indicators derived from the HFPE evidence standard that pharmaceutical market access and HEOR teams cannot access through claims data, EHR aggregations, or any existing real world data vendor.
Lumaris surfaces six additional proprietary KPIs across behavioral, clinical, predictive, and data quality signal categories. The full KPI architecture is available to Lumaris partners upon execution of a data partnership agreement. Contact us to discuss what the complete evidence framework looks like for your therapeutic area.
Structured data collection in existing real world platforms drops sharply after the first two weeks following discharge. Claims data thins out, EHR entries stop, and prescription fill records capture only a billing transaction with no behavioral context attached. This gap occurs precisely during the window when most adherence failures originate and most readmissions are set in motion.
The gap between the two lines below represents 76 days of behavioral and social evidence that pharmaceutical companies cannot access through any existing real world data vendor, regardless of how large their patient database is.
Partnership pricing for both tiers is structured based on network scale, therapeutic area scope, and evidence maturity at the time of agreement. Contact us to discuss what a Lumaris partnership looks like for your organization.
A pharmaceutical company with drugs in a relevant therapeutic area subscribes for access to aggregate cohort level evidence across the Trisana hospital network for their disease category. This tier is structured for organizations that want population level intelligence on patient behavior in their therapeutic area, with founding partner pricing available to early participants that is locked for the life of the agreement.
A pharmaceutical company enters a more specific data use agreement scoped to patients discharged on their particular therapeutic agent, receiving evidence directly tied to their drug's real world performance in the post discharge window. This tier is structured for organizations that need drug specific adherence evidence, SDOH-outcomes correlation for a defined patient subgroup, and regulatory grade evidence outputs.
Founding partners access the Lumaris evidence framework at the lowest price point in the program's history, with pricing locked for the life of the agreement. As the hospital network scales and patient data volume grows, the value of the evidence partnership grows with it. Early partners shape the evidence framework in ways that later partners cannot.